**Shares of clinical-stage immune-oncology co Imugene
rise as much as 14.6% to A$0.055; biggest intraday pct gain since Sept. 2
** U.S. FDA gives orphan drug status to co's VAXINA treatment, aimed at treating cholangiocarcinoma, a form of bile tract cancer
** FDA grants orphan drug status to promote drug development for rare diseases affecting fewer than 200,000 people in the U.S.
** Co says orphan status gives it range of incentives including tax credits, potential grant funding and 7-year market exclusivity
** About 56.7 mln shares change hands vs 30-day avg volume of about 23.7 mln shares
**Stock down 54.5% YTD
(Reporting by Nikita Jino in Bengaluru)
((Nikita.Jino@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。